The content on this site is intended for healthcare professionals only
Dr Sherene Loi talks to ecancer about the heterogeneity of breast cancer tumours at IMPAKT 2012 in Brussels, May 2012.
Technology now allows for the understanding of the cancer genome down to the base pair of certain types of cancer. In small tumour breast cancer, less than 2cm, the tumours have multiple ‘clones’ and these ‘clones’ drive the growth of the tumour. Treatment of one tumour can be the reason for relapses as another tumour can then proliferate.
Dr Loi also discusses PI3 kinase, which is essential for cell growth but highly irregular in breast cancer and especially in triple negative breast cancer where no targeted therapies yet exist.
Filming Supported by Amgen
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
IORT at the Asian Hospital and Medical Center
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
